Business Wire

Comprehensive and Reliable Total Nucleic Acid Extraction from FFPE Samples with Covaris truXTRAC® FFPE SMART Solutions

Share

Covaris, LLC, a leader in pre-analytical sample preparation technologies, proudly unveils a comprehensive, fully automatable deparaffinization and total nucleic acid extraction workflow for formalin-fixed paraffin-embedded (FFPE) samples. Covaris truXTRAC FFPE SMART Solutions are designed for use with Covaris’ high-throughput focused-ultrasonicators and include all reagents, consumables, and accessories used in the workflow that caters to a wide range of throughput requirements.

Combining truXTRAC FFPE SMART Solutions with Covaris’ class-leading Adaptive Focused Acoustics® (AFA®) technology offers laboratories working with FFPE tissues high-quality DNA and RNA recovery in a scalable, efficient workflow that can be partially or fully automated from deparaffinization through isolation and purification steps. ​All this can be achieved while addressing throughput requirements and providing reliable, robust, and reproducible results. Covaris truXTRAC FFPE SMART Solutions ensure extraction and purification of DNA as well as RNA, which is otherwise difficult to process from FFPE samples. Compared to traditional workflows for FFPE samples, truXTRAC FFPE SMART Solutions do not require use of any harmful organic solvents such as xylene or hexadecane. The customized accessories included in truXTRAC FFPE SMART Solutions allow each step within the workflow to be automated and are compatible with most automated liquid handlers and on-deck or deck-adjacent instruments, such as capper/decappers, centrifuges, and Covaris’ R230 or LE220 focused-ultrasonicators.

The high-throughput focused-ultrasonicators highlighted in the workflow feature Covaris’ patented AFA technology. Using active, non-contact, mechanical deparaffinization, this technology enables complete and efficient deparaffinization without the use of harsh chemicals, resulting in recovery of high-quality DNA and RNA, while maintaining data reliability and reproducibility.

“FFPE samples contain critical information about a person’s health and hence are investigated in an array of application types,” said Annemarie Watson, CEO of Covaris, LLC. “Covaris’ truXTRAC FFPE SMART Solutions ensure high quality and yield of DNA and RNA while addressing a wide range of throughput requirements. These advantages enable researchers to generate confident, meaningful results that have impact in medical and scientific communities.”

About Covaris

Based in Woburn, MA, Covaris develops, manufactures, and markets instruments, consumables, and reagents used in pre-analytical sample preparation for genomic and proteomic analysis to help accelerate the pace of research and life science innovations. Using proprietary technologies including focused acoustic energy, Covaris’ tools achieve highly accurate and reproducible results with the goal of empowering customers to make new discoveries, develop new assays and improve bioanalytical results. Some of the non-contact applications include faster automated DNA fragmentation, cell lysis, accelerated binding partner mixing, bead resuspension, and compound formulation.

Additional information about Covaris, LLC is available at www.covaris.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Kate Meola
Covaris, Inc.
+1 781-932-3959
kmeola@covaris.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LambdaTest and SVAM International Inc. Announce Partnership to Transform Quality Engineering for Businesses26.11.2025 19:00:00 EET | Press release

LambdaTest, a Gen-AI native quality engineering platform, announced a partnership with SVAM International, Inc., a global leader in digital transformation services. This strategic alliance marks a significant step forward in their mission to transform quality engineering for businesses worldwide. The partnership allows LambdaTest to extend its AI-native quality engineering capabilities into SVAM’s extensive digital transformation ecosystem. By integrating with SVAM’s experience in large-scale application development, testing, and delivery across major New York State and City agencies, as well as their platform expertise across Salesforce, ServiceNow, and Dynamics365, LambdaTest will empower more enterprises to modernize their software delivery pipelines. With LambdaTest’s intelligent test orchestration and execution engine at the core, teams can test smarter, accelerate release cycles, and achieve faster time-to-market at scale. Founded in 2017, LambdaTest is headquartered in San Franc

GLORY Acquires Remaining Equity Shares in Acrelec Group26.11.2025 17:11:00 EET | Press release

Glory Global Solutions (International) Ltd, a wholly-owned subsidiary of GLORY Ltd. [TYO:6457], has announced the acquisition of the remaining equity shares in Acrelec Group SAS. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251126039437/en/ Acrelec is a global technology company focused on reinventing the customer experience for restaurant and retail brands. Leveraging decades of software, hardware and service expertise, the company develops and integrates new platforms that increase customer engagement, optimize efficiency and improve operations. With over 120,000 installations across more than 70 countries, Acrelec counts many of the world’s best-known restaurant mega-brands among its customers. We announce that Jalel Souissi has left the Acrelec Group following the completion of the recent share acquisition. Jalel Souissi has played a pivotal role in the development and success of Acrelec, serving as Co-Founder and Co-C

Cegid Acquires Shine to Accelerate the Path of Becoming Europe's Leading Financial Copilot for SMBs and Accountants26.11.2025 15:00:00 EET | Press release

Cegid, a European leader in cloud software for finance, accounting, HR, and retail software, and Shine, a fast-growing European fintech unicorn providing digital business accounts and payments, e-invoicing, accounting, and payroll software to small businesses across Europe, announced today that the companies have entered a definitive agreement to join forces to form a European champion and become a leading provider of software for businesses and their accountants. This transformational combination will create the first fully integrated, cloud-native and AI-driven financial hub for SMBs and accounting professionals in Europe – bringing together market-leading capabilities in e-invoicing, accounting, digital business accounts and payments, tax, HR, and payroll in a single unified platform. Accelerating Cegid’s European growth strategy by serving more than one million SMBs, and 15,000 accountants Shine brings to Cegid more than 400,000 SMB customers, a strong brand, and a highly scalable

U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma26.11.2025 13:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to a New Drug Application (NDA) for sonrotoclax, a next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase (BTK) inhibitor. “Sonrotoclax is advancing with remarkable speed, from Breakthrough Therapy Designation to Priority Review, all within a short window,” said Lai Wang, Ph.D., Global Head of R&D at BeOne. “That pace reflects both the strength of the data and the urgency of the need for patients with R/R MCL. With rapid, deep, and durable responses and a manageable safety profile, sonrotoclax is emerging as a potential best-in-class BCL2 inhibitor, alongside our two other transformative hematology assets – BTK inhibitor BRUKINSA, and investigational BTK degrader BGB-16

Modon Holding Announces a Strategic Investment in Wellington Lifestyle Partners, Expanding Its Global Portfolio in Luxury Lifestyle Destination Development26.11.2025 12:15:00 EET | Press release

Abu Dhabi-based Modon Holding P.S.C (“Modon”) today announced a strategic investment in Wellington Lifestyle Partners (“WLP”), joining a consortium of existing investors in the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251125937208/en/ Aerial shot of Wellington International (Photo: AETOSWire) Modon’s investment will support the long-term development of Wellington International equestrian showgrounds and deliver a landmark ultra-luxury real estate development featuring high-end residences, a boutique hotel, a commercial marketplace and a championship golf course located in Wellington, Florida – a global icon of equestrian sport. This investment marks Modon’s first direct investment in an equestrian led development in the United States, complementing its existing global portfolio, and reinforcing its strategy to partner with leading international organisations in expanding its presence across ultra-luxury destin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye